Pages that link to "Q52969087"
Jump to navigation
Jump to search
The following pages link to Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort. (Q52969087):
Displaying 27 items.
- Active surveillance and focal therapy for low-intermediate risk prostate cancer (Q26773641) (← links)
- CCAFU french national guidelines 2016-2018 on prostate cancer (Q30241244) (← links)
- Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer (Q37060938) (← links)
- Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies (Q37418080) (← links)
- Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry - Victoria (Q37496914) (← links)
- CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. (Q37563750) (← links)
- Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy. (Q38519540) (← links)
- Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer (Q38588658) (← links)
- Population-based study of grade progression in patients who harboured Gleason 3 3. (Q38788460) (← links)
- What is the best way not to treat prostate cancer? (Q38799211) (← links)
- Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities (Q38846321) (← links)
- PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER. (Q39108592) (← links)
- Active Surveillance in Younger Men With Prostate Cancer. (Q40271880) (← links)
- Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. (Q40572565) (← links)
- Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer (Q42374568) (← links)
- Epigenetic risk score improves prostate cancer risk assessment (Q43152996) (← links)
- Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions (Q48681310) (← links)
- Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. (Q52624211) (← links)
- Younger Men With Prostate Cancer Have Lower Risk of Upgrading While on Active Surveillance: A Meta-analysis and Systematic Review of the Literature (Q57109233) (← links)
- Active surveillance for low-risk prostate cancer (Q57124371) (← links)
- Comparison of conventional transrectal ultrasound, magnetic resonance imaging, and micro-ultrasound for visualizing prostate cancer in an active surveillance population: A feasibility study. (Q64913973) (← links)
- Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results (Q89845717) (← links)
- 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort (Q90031913) (← links)
- Utility of digital rectal examination in a population with prostate cancer treated with active surveillance (Q90730005) (← links)
- Micro-Ultrasound Imaging for Accuracy of Diagnosis in Clinically Significant Prostate Cancer: A Meta-Analysis (Q92541784) (← links)
- Prediction of pathologic upgrading in Gleason score 3 4 prostate cancer: Who is a candidate for active surveillance? (Q97527417) (← links)
- [French ccAFU guidelines - update 2020-2022: prostate cancer] (Q104517654) (← links)